Benitec Biopharma Inc.
BNTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001808898
No open-market purchases or sales by Benitec Biopharma Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q2 2026, worth $443.3M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Benitec Biopharma Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- −5 vs. Q2 2023
- Shares held
- 1.27M
- +617.6K (+95.0%) vs. Q2 2023Converted for a 1-for-17 split
- Total value
- $3.84M
- +$1.38M (+56.4%) vs. Q2 2023
- New holders
- 3
- 6 more added
- Sold out
- 8
- 1 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BNTC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 86 | $443.3M |
| Q1 2026 | 88 | $346.0M |
| Q4 2025 | 72 | $426.6M |
| Q3 2025 | 56 | $324.7M |
| Q2 2025 | 57 | $265.3M |
| Q1 2025 | 37 | $290.1M |
| Q4 2024 | 30 | $240.2M |
| Q3 2024 | 25 | $126.8M |
| Q2 2024 | 19 | $44.3M |
| Q1 2024 | 13 | $6.58M |
| Q4 2023 | 13 | $3.88M |
| Q3 2023 | 12 | $3.84M |
| Q2 2023 | 17 | $2.45M |
| Q1 2023 | 21 | $2.44M |
| Q4 2022 | 25 | $2.09M |
| Q3 2022 | 25 | $5.92M |
| Q2 2022 | 22 | $1.55M |
| Q1 2022 | 21 | $2.60M |
| Q4 2021 | 17 | $4.16M |
| Q3 2021 | 19 | $5.43M |
| Q2 2021 | 18 | $6.46M |
| Q1 2021 | 15 | $1.84M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Benitec Biopharma Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 13 | $39 | 0.00% | +1+9.4% | AddedConverted for a 1-for-17 split |
| Rosenberg Matthew Hamilton | 23 | $70 | 0.00% | +1+2.6% | AddedConverted for a 1-for-17 split |
| Group One Trading, L.P. | 89 | $269 | 0.00% | +1+0.9% | AddedConverted for a 1-for-17 split |
| UBS Group AG | 109 | $329 | 0.00% | +89+434.0% | AddedConverted for a 1-for-17 split |
| Rhumbline Advisers | 186 | $561 | 0.00% | 00.0% | UnchangedConverted for a 1-for-17 split |
| Tower Research Capital LLC (TRC) | 196 | $592 | 0.00% | −243−55.4% | ReducedConverted for a 1-for-17 split |
| Geode Capital Management, LLC | 10,024 | $30.3K | 0.00% | +7,187+253.4% | AddedConverted for a 1-for-17 split |
| Citadel Advisors LLC | 69,515 | $209.9K | 0.00% | +69,515 | New |
| Adage Capital Partners GP, L.L.C. | 189,188 | $571.7K | 0.00% | +189,188 | New |
| Suvretta Capital Management, LLC | 204,220 | $617.1K | 0.03% | +158,985+351.5% | AddedConverted for a 1-for-17 split |
| Janus Henderson Group PLC | 206,170 | $630.9K | 0.00% | +206,170 | New |
| Franklin Resources Inc | 588,237 | $1.78M | 0.00% | 00.0% | UnchangedConverted for a 1-for-17 split |
| Vanguard Group Inc | 0 | $0 | 0.00% | −4,398−100.0% | Sold outConverted for a 1-for-17 split |
| Virtu Financial LLC | 0 | $0 | 0.00% | −3,110−100.0% | Sold outConverted for a 1-for-17 split |
| Morgan Stanley | 0 | $0 | 0.00% | −2,271−100.0% | Sold outConverted for a 1-for-17 split |
| State Street Corp | 0 | $0 | 0.00% | −1,261−100.0% | Sold outConverted for a 1-for-17 split |
| Private Advisor Group, LLC | 0 | $0 | 0.00% | −774−100.0% | Sold outConverted for a 1-for-17 split |
| WealthTrust Axiom LLC | 0 | $0 | 0.00% | −762−100.0% | Sold outConverted for a 1-for-17 split |
| Northern Trust Corp | 0 | $0 | 0.00% | −695−100.0% | Sold outConverted for a 1-for-17 split |
| Cutler Group LP | 0 | $0 | 0.00% | −59−100.0% | Sold outConverted for a 1-for-17 split |